Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

Tango Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Highlights